|
|
Post by thekindaguyiyam on Jun 22, 2016 13:51:22 GMT -5
|
|
|
|
Post by centralcoastinvestor on Jun 22, 2016 14:20:34 GMT -5
I tried using this link and it says page not found. I went to the website directly and found the article. It's nice to see a well written, bullish article. Here's hoping there is more to come. |
|
|
|
Post by thekindaguyiyam on Jun 22, 2016 14:29:52 GMT -5
it was posted within an hour of my finding it. It's familiar to us... here's some of it that I copied.
"MannKind (MNKD) Stock: Big Gains Ahead!
MannKind (MNKD) Stock: Big Gains Ahead!
MannKind Corporation (NASDAQ: MNKD)
MannKind has had a rough time over the past year, and for good reason. The company contracted with a competitor for the launch of its flagship product. Unfortunately, that didn’t work out so well. Nonetheless, they are moving forward with the second Afrezza launch, and things are looking much better. Today, we’ll talk about the new launch, what we’re seeing in the market as a result, and what we can expect to see from MNKD moving forward.
MNKD Will Move Forward With Afrezza Launch
The last launch of Afrezza was horrible. While Sanofi took control over the treatment, we didn’t see much movement. MannKind suffered as we saw very few ads, little by way of outreach to physicians and patients, and ultimately a horrible commercialization plan. However, this time things are very different. What is being called Afrezza Launch 2.0 will be starting in July of this year. Here are the key difference between the two campaigns…
MNKD Is In Charge – First and foremost, it’s important to note that MannKind had little influence on what happened with the first launch. It was all Sanofi. However, this time around, MNKD is holding the steering wheel, and that’s important. After all, the company’s fate rides on this launch. So, they are going to do everything in their power to make sure it is a positive one.
Solid Data – During the first launch, there wasn’t nearly as much data surrounding Afrezza as there is now. This means that MNKD will have the ability to create better presentations. As a result, the company will likely have an easier time building an audience and gaining trust among physicians.
Sales Team – When Sanofi did the launch of Afrezza, the company had a botched sales team on the job at best. However, this time around, MNKD has created a dedicated sales force. The new team has targeted directives and is focused solely on sales of Afrezza.
Strong Partnership – Another factor that MannKind has going for it this time is that it recently entered into a partnership with JDRF. This foundation, previously known as Juvenile Diabetes Research Foundation, is focused on molding Afrezza as a strong insulin for the pediatric market. The two will also work together to advance the treatment of diabetes… much of this advancement is likely to revolve around Afrezza.
What We’re Seeing In The Market
It’s clear that investors are excited about the Afrezza Launch 2.0, and why wouldn’t they be. This move will likely lift sales and lead to revenue growth for MNKD. As a result, we’re seeing strong gains in the value of the stock today. Currently (10:57), the stock is trading at $1.15 per share after a gain of $0.08 per share or 7.48% thus far today.
Find out how you can trade stocks like the pros without major time commitments!
What We Can Expect To See Moving Forward
Moving forward, I have an overwhelmingly bullish opinion of whaot we can expect to see from MannKind. The reality is that with Afrezza, the company has done something amazing for the diabetic community. After all, would you rather take your medicine through an inhaler or through a needle. The treatment is a much needed one among the pediatriPn plan, I’m expecting for Afrezza to sell incredibly well. This will likely send MNKD soaring for the long run."
An article posted on "modest money" site. do a google search afrezza last 24 and it comes up viewable
|
|
|
|
Post by nylefty on Jun 22, 2016 16:42:58 GMT -5
This foundation, previously known as Juvenile Diabetes Research Foundation, is focused on molding Afrezza as a strong insulin for the pediatric market. The two will also work together to advance the treatment of diabetes… much of this advancement is likely to revolve around Afrezza.
Really? Much as I'd like to see this, I've seen no evidence that JDRF is "focused" on doing any such thing.
|
|
|
|
Post by mannmade on Jun 22, 2016 16:56:34 GMT -5
As an FYI, they changed their name to JDRF to take the focus off pediatrics and allow for a broader member base that would appeal to adult diabetics.
|
|
